Development of novel 5‐fluorouracil carrier erythrocyte with pharmacokinetics and potent antitumor activity in mice bearing malignant ascites

Publisher： John Wiley & Sons Inc

E-ISSN： 1440-1746|25|5|985-990

ISSN： 0815-9319

Source： JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol.25, Iss.5, 2010-05, pp. : 985-990

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Comparative Antitumor Activity of 5-Fluorouracil and 5’-Deoxy-5-Fluorouridine in Combination with Interferon-α in Renal Cell Carcinoma Cell Lines

By  

Urologia Internationalis, Vol. 73, Iss. 4, 2004-12 ,pp. : 348-353

Karger

Access to resources Recommend Favorite

Prevention of Peritoneal Metastasis of Human Gastric Cancer Cells in Nude Mice by S-1, a Novel Oral Derivative of 5-Fluorouracil

By  

Oncology, Vol. 64, Iss. 2, 2003-02 ,pp. : 176-182

Karger

Access to resources Recommend Favorite

Safety and Efficacy of S-1, a Novel Oral Fluorouracil Antitumor Drug, for a Chronic Renal Failure Patient Maintained on Hemodialysis

By  

Oncology, Vol. 66, Iss. 5, 2004-09 ,pp. : 358-364

Karger

Access to resources Recommend Favorite

Pharmacokinetics of 1α,25-Dihydroxyvitamin D3 in Normal Mice after Systemic Exposure to Effective and Safe Antitumor Doses

By  

Oncology, Vol. 66, Iss. 1, 2004-03 ,pp. : 62-66

Karger

Access to resources Recommend Favorite

Potent antitumor activity of cabozantinib, a c‐MET and VEGFR2 inhibitor, in a colorectal cancer patient‐derived tumor explant model

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 136, Iss. 8, 2015-04 ,pp. : 1967-1975

John Wiley & Sons Inc

Access to resources Recommend Favorite